Isobologram analysis of triple therapies by Niyazi, Maximilian & Belka, Claus
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Radiation Oncology
Open Access Methodology
Isobologram analysis of triple therapies
Maximilian Niyazi* and Claus Belka
Address: CCC Tübingen, Department of Radiation Oncology, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany
Email: Maximilian Niyazi* - maxi@niyazi.de; Claus Belka - claus.belka@uni-tuebingen.de
* Corresponding author    
Abstract
New concepts in radiation oncology are based on the concept that combinations of irradiation and
molecular targeted drugs can yield synergistic or at least additive effects. Up to now the
combination of two treatment modalities has been tested in almost all cases. Similar to
conventional anti-cancer agents, the efficacy of targeted approaches is also subject to predefined
resistance mechanisms. Therefore, it seems reasonable to speculate that a combination of more
than two agents will ultimately increase the therapeutic gain. No tools for a bio-mathematical
evaluation of a given degree of interaction for more than two anti-neoplastic agents are currently
available.
The present work introduces a new method for an evaluation of triple therapies and provides some
graphical examples in order to visualize the results.
Background
Many mathematical approaches have been described in
order to determine the level of interaction of two agents.
In this regard, isobologram analysis was developed and
described 30 years ago and is still the most popular tool
for this question [1,8]. Basically, isobologram analyses are
an approach to represent zero-interaction curves of two
agents. However, classical isobologram analyses are quite
resource intensive and therefore a widespread use has
never been adopted.
Although the combination of two agents was effective in
many clinical settings, a combination of three or more
treatment principles is even more realistic.
In case of radiation oncology it has been shown that the
inhibition of EGF-R in combination with radiation using
the C225 antibody was effective in terms of local control
and survival [4]. However, cis-platinum based radiochem-
otherapy represents the current standard approach for
advanced head and neck cancer. Currently the combina-
tion of radiation, cis-platinum and C225 is tested clini-
cally while still lacking a complete preclinical evaluation
of the combined therapy [7].
Although targeted agents are clearly effective [6], like for
conventional agents the long term efficacy is hampered by
specific resistance mechanisms. Therefore it seems to be
likely that in the future combinations of distinct and/or
interactive targeted drugs will be used in clinical settings.
The present work provides a new mathematical formalism
to analyse the level of interaction of three treatment
approaches based on a reduced scale data set.
Theoretical background
Before introducing any mathematical detail, it is of crucial
importance to define the terms used within this paper:
The semantic definition of synergy describes an interac-
tion that is more effective than the sum of the single
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effects (known by the famous holistic saying "the whole is
more than the sum of its parts"). Therefore the term syn-
ergy or "supra-additivity" describes situations where the
combination of agents acts more than additive [2].
The two classical definitions of additivity go back to
Loewe [5] and Bliss [3]. Bliss developed the model of
response additivity which is also called the criterion of
Bliss independence. These definitions are not only formal
thoughts but do have some practical implications [8]
which are especially important in the field of radiation
oncology. Response additivity means that we assume sta-
tistical independence which leads to a pure addition of
the effects. In contrast, dose-additivity assumes that the
agents behave like simple dilutions and act without self-
interaction. In this case it has become popular to talk of
zero-interactive responses.
For this purpose Berenbaum developed the following for-
mula:
where di is the actual dose (concentration) of the individ-
ual agents in a combination and Di is the dose (concentra-
tion) of the agents that individually would produce the
same effect as the individual compounds in the combina-
tion [1].
By handling linear dose-response-curves one only gets a
straight line of additivity which divides the plane into the
areas "supra-additive" and "infra-additive".
As one usually considers dose-response-relationships that
are non-linear, these two concepts will lead (in the case of
two agents/modalities) to an envelope of additivity.
The different concepts are made clear by an example (see
Fig. 1):
If one assumes a quadratic dose-response relationship for
one of the agents (therapy 1) and a linear relationship for
a less effective drug (therapy 2) and if one furthermore
needs one dose unit of therapy 1 to obtain 10% of the
maximum effect (Emax) and four dose units of therapy 2 d
D
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In this diagram two dose-response-relationships are plotted whereas Emax denotes the fraction of the maximum effect Figure 1
In this diagram two dose-response-relationships are plotted whereas Emax denotes the fraction of the maximum effect. Therapy 
1 is quadratic (y = 10 x2) and therapy 2 is linear (y = 2,5 x). One needs one dose unit of therapy 1 to obtain 10% of the maxi-
mum effect and four dose units of therapy 2 for the same effect; so a combination would yield (in the strict response additive 
case) 20%. In the case of Loewe-additivity one would analyse as follows: therapy 2 yields the same like one unit of therapy 1. So 
the effect would be the same as for two units of therapy 1, namely 40%.
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for the same effect, a combination would yield (in the
strict response additive case) 20%. In the case of Loewe-
additivity this would lead to the following: therapy 2
yields the same like one unit of therapy 1. So the effect
would be the same as for two units of therapy 1, namely
40%!
Formal definitions
Now one has to focus on the effect of the single agents.
The effect can e. g. be the rate of apoptosis, the amount of
dead cells or something similar. The following theory can
readily be modified and is completely analogous if one
measures surviving fractions. In this case -ln(SF) has to be
regarded as the effect where the logarithm is a contribu-
tion to the definition of the suriving fraction; this means
that surviving fractions are multiplicatively connected
while the natural logarithms are additive.
In order to describe the relationship mathematically, the
following notation is introduced:
yj = fj (xj), j ∈ {1, 2, 3},
where y denotes the effect and x the dose/concentration of
XRT or the drug (in the following the term "dose" is used
for both concepts). The functions fj should be continuous
and invertable (i. e. bijective). The inverse functions will
be denoted by f-1
j.
Let dj be the dose of the jth modality in the triple therapy.
Therapies will be denoted as (d1|d2|d3); d1 relates to the
concentration of a hypothetical agent A [μg/ml] (the units
are suppressed during the calculations), d2 is the concen-
tration of another agent B [nM] and d3 denotes the dose of
(X)RT [Gy].
Concept
First the surface of strict response additivity will be intro-
duced. It is the surface that contains all combinations
which would produce an effect that equals the effect of the
triple therapy (the corresponding dose is called isoeffect-
dose or in brief isodose). It is denoted by "i". The first for-
mula may thus be written as
which represents a three-dimensional surface in space.
The presented semantic definitions furthermore lead to
the following seven equations:
f-1
3(f1(x1)) + f-1
3(f2(x2)) + x3 = f-1
3(i)   [3]
f-1
3(f2(f-1
2(f1(x1)) + x2)) + x3 = f-1
3(i)   [4]
f-1
3(f1(f-1
1(f2(x2)) + x1)) + x3 = f-1
3(i)   [5]
f2(f-1
2(f1(x1)) + x2) + f3(x3) = i   [6]
f1((f-1
1(f2(x2)) + x1) + f3(x3) = i   [7]
f3 
-1(f1(x1) + f2(x2)) + x3 = f-1
3(i)   [8]
f3(f-1
3(f1(x1)) + f-1
3(f2(x2))) + f3(x3) = i   [9]
Most of these equations use a mixed definition for "addi-
tivity" namely dose (or Loewe) and response additivity as
mentioned above.
Cyclic permutation of these seven equations leads to the
other 14 equations.
By further investigation it can be shown that these overall
22 equations are complete which would be beyond the
scope of this paper.
For practical use it will be sufficient to examine the two
outer surfaces which contain the "volume of additivity"
and to determine where the "point of therapy" is located.
As shown later, it is not evident what these two surfaces
are.
Example
After considering the general purpose of isobologram
analysis, the following attempt is used to demonstrate a
special example:
fj (xj) = aj ln xj + bj, j ∈ {1, 2}, f3 (x3) = a3 x3 + b3   [10]
In this notation f3 denotes the effect of (X)RT and aj, bj are
parameters to be determined from the experiment. The
"effect" may be "cell death induction" or in our case
"induction of apoptosis". All coefficients and required
parameters are listed in Tab. 1 and Tab. 2.
It depends on the experimental design whether [10] is
useful or not. For clonogenic assays in vitro or growth
delay experiments in vivo one should actually use linear-
quadratic approaches.
One must keep in mind that the used equations describe
extrapolated curves which try to predict the effect for
doses which cannot be tested (so it is more reliable to use
an established model).
Now one has to evaluate all calculated equations. The
result is a set of 22 implicitly given surfaces which can be
plotted.
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With respect to [10] one has to remark that some of the
equations are identical (as f3 is linear).
The corresponding solutions in an explicit manner will be
of the form xk = g(xi, xj). Beside the three-dimensional rep-
resentation it will be useful to plot the cuts through the
point (d1|d2|d3). This is easily performed by setting xi = di,
i ∈ {1, 2, 3}.
Here are some of the solutions (the number of the for-
mula with a star corresponds to the above mentioned
equation without star):
[8] and [9] have an identical solution because of the
above mentioned linearity of f3. Overall, there are 5 equa-
tions which are redundant so that there are 17 distinct sur-
faces at the end.
Some of the surfaces have no real solutions in certain
domains of the space. In these special cases a 2D represen-
tation helps to decide whether the point of therapy lies in
the domain of synergism or not.
It can be shown that the solutions are unique (which is a
consequence of the bijective attempt [10]). This proof
would be beyond the scope of the paper.
The solution of [2] is shown in Fig. 2a – c, the plot is pre-
sented from three different perspectives. All 22 equations
are plotted together in Fig. 3. By analysing the surfaces
more accurately it seems that [2] represents the innermost
surface.
As it is a question of perspective whether one realizes that
the point lies under the innermost surface, one can plot a
two-dimensional graph as indicated before which is done
in Fig. 4. From Fig. 4b it can be deduced that [2] is not
completely the innermost surface.
It is interesting that in Fig. 4 there seem to be less curves
than equations. There are two simple reasons: 1) some
equations are identical as mentioned above, 2) some
equations produce different results but are very similar to
other equations so that they cannot be differentiated visu-
ally.
The isobole surfaces for linear-quadratic approaches were
also determined according to the above mentioned equa-
tions. We plotted inner- and outermost surface as well as
the point of therapy. The results are shown in Fig. 5a – d.
We provide (as a supplement to this paper) two small pro-
grammes which the reader can use for his own experimen-
tal data (a detailed description is also included) [see
Additional files 1, 2 and 3].
Statistics
Similar as for two-dimensional isobolograms [9] a sepa-
rate statistical analysis is required in our case. As one
assumes the regression curves for the agents/XRT to be
"exact", it is possible to calculate a new isobologram
which corresponds to the lower limit of the 95 % confi-
dence interval of the isodose (which corresponds to [i -
1,96 × SEM]). So we are able to elucidate if the triple
remains synergistic. In this case we would be allowed to
call the synergism "significant".
Discussion
Starting from the semantic definition of "synergy" and the
problem to evaluate a combination of three modalities we
developed a system of 22 equations which enable the user
to derive the correct type of interaction.
This is a new aspect according to the classically used "com-
bination index" [10] which only focuses on one of the 22
surfaces.
From the reported theory the following may be obtained:
1) It leads to a far wider concept of additivity. Thus it is
important to define what definition is used.
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a, b, c: Shown is the surface of strict response additivity for the triple therapy 5 [Gy] + 0.001 [μg/ml] A + 1 [nM] B from three  different perspectives Figure 2
a, b, c: Shown is the surface of strict response additivity for the triple therapy 5 [Gy] + 0.001 [μg/ml] A + 1 [nM] B from three 
different perspectives. The axes are labeled with the dose/concentrations of the single agents (x1: A, x2: B, x3: XRT) in a right-
handed cartesian coordinate system. The plot ranges are [0, 10] for XRT, [0, 0.1] for A and [0, 100] for B. The black dot marks 
the "point of therapy" namely (0.001|1|5); x1 = 0.001 and x2 = 1 means that the point is close to the x3-axis. The "point of ther-
apy" lies in the middle of the plot range [0, 10].
ab
c
All 17 surfaces are plotted for the therapy (0.001|1|5), the point of therapy was also included. In order to show all these sur- faces the x3-axis (RT) was extended Figure 3
All 17 surfaces are plotted for the therapy (0.001|1|5), the point of therapy was also included. In order to show all these sur-
faces the x3-axis (RT) was extended.Radiation Oncology 2006, 1:39 http://www.ro-journal.com/content/1/1/39
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a - c: Displayed are the 2D cuts through the three-dimensional plot in Fig. 3; shown are the layers which contain the point of  therapy (0.001|1|5) Figure 4
a - c: Displayed are the 2D cuts through the three-dimensional plot in Fig. 3; shown are the layers which contain the point of 
therapy (0.001|1|5). Fig. 4 a: x2 - x3-plane (x1 = d1 is fixed), b: x1 - x3-plane, c: x2 - x1-plane.
ab
c
a - d: This shows the volume of additivity for four different cases; displayed are only inner- and outermost surface of additivity,  the point of therapy is again included Figure 5
a - d: This shows the volume of additivity for four different cases; displayed are only inner- and outermost surface of additivity, 
the point of therapy is again included. 5 a shows the case for three linear dose-response-relationships. As expected one gets a 
single plane (corresponding to the straight line in the 2D case). 5 b is calculated by using one linear and two linear-quadratic 
equations, 5 c uses two linear and one linear-quadratic equation and 5 d is calculated by three linear-quadratic equations.
ab
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2) It is often difficult to get out the mechanisms on the
molecular layer but isobologram analysis has managed to
handle these combined therapies and allows to deduce
some of the biological effects behind the therapy.
This means that a synergism can under certain circum-
stances be a useful tool to elicit which combinations
might make sense for clinical trials.
For this purpose strict conditions should be set up to
determine which one of the combinations is really prom-
ising. The given equations (in their general form) provide
the necessary mathematical formalism for this purpose.
One problem remains: how can we decide whether a
given triple therapy acts in a "more synergistic" way than
a combination of just two modalities?
It was only shown that the triple therapy is synergistic
with respect to the effects of the single modalities. When
using isobologram analysis there is no other possibility as
a double combination is not feasible as a free parameter.
For practical purposes it is necessary to determine whether
a given triple therapy is a "good" therapy. Our attempt is
to elucidate if the combination is synergistic and as a sec-
ond criterion it has to be significantly better than the cor-
responding double combinations (which means that
synergy is a necessary, but no sufficient criterion for a
"good" therapy); one additionally has to compare the
effects of double therapies and triple therapy in a bar
graph. This is shown in Fig. 6.
Table 2: Doses for the triple therapy RT + A + B and level of 
isodose
i [%] d1 [μg/ml] d2[nM] d3[Gy]
52 0.001 1 5
This bar graph displays control, single, double and triple therapies for the therapy (0.001|1|5) Figure 6
This bar graph displays control, single, double and triple therapies for the therapy (0.001|1|5). It is important that RT + A + B is 
significantly better than the corresponding double combinations A + B, RT + A and RT + B. Synergy alone is not sufficient to 
guarantee this.
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Table 1: Coefficients for the parametric representations of the 
dose-response-relationships
a1 a2 a3 b1 b2 b3
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Materials and methods
Mathematical calculations and graphical evaluation were
performed by the use of Mathematica 5.2 for students®,
Wolfram Research (Friedrichsdorf, Germany).
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Additional File 1
Isobolyzer - a tool for isobologram analysis of triple therapies. A help-file 
for the two delivered programmes, containing advice for installation, use 
and handling.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1748-
717X-1-39-S1.pdf]
Additional File 2
Isobolyzer for linear-quadratic dose-response-relationships. This Excel 
macro enables the user to type in his own experimental data. The used 
dose-response-relationships are linear-quadratic.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1748-
717X-1-39-S2.xls]
Additional File 3
Isobolyzer for two logarithmic and one linear dose-response-relationship. 
This Excel macro enables the user to type in his own experimental data. 
The used dose-response-relationships are linear and logarithmic.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1748-
717X-1-39-S3.xls]